NASDAQ:SNTI

Senti Biosciences (SNTI) Stock Forecast, Price & News

$0.88

-0.07 (-7.34%)

(As of 05/31/2023 ET)

Compare

Today's Range: $0.86
▼
$0.95
50-Day Range: $0.88
▼
$1.26
52-Week Range: $0.86
▼
$9.96

Volume: 68,436 shs
Average Volume: 99,844 shs
Market Capitalization: $39.04 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.50

Senti Biosciences MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 409.1% Upside
$4.50 Price Target
Short Interest: Bearish
2.01% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.54) to ($0.99) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars

Medical Sector

729th out of 1,006 stocks

Biological Products, Except Diagnostic Industry

116th out of 167 stocks

3.3

Analyst's Opinion

Consensus Rating
Senti Biosciences has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $4.50, Senti Biosciences has a forecasted upside of 409.1% from its current price of $0.88.
Amount of Analyst Coverage
Senti Biosciences has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
2.01% of the float of Senti Biosciences has been sold short.
Short Interest Ratio / Days to Cover
Senti Biosciences has a short interest ratio ("days to cover") of 5.8.
Change versus previous month
Short interest in Senti Biosciences has recently increased by 2.86%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Senti Biosciences does not currently pay a dividend.
Dividend Growth
Senti Biosciences does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for SNTI.

1.5

News and Social Media Coverage

News Sentiment
Senti Biosciences has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.
Search Interest
Only 1 people have searched for SNTI on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Senti Biosciences insiders have not sold or bought any company stock.
Percentage Held by Institutions
40.81% of the stock of Senti Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Senti Biosciences are expected to grow in the coming year, from ($1.54) to ($0.99) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Senti Biosciences is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Senti Biosciences is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Senti Biosciences has a P/B Ratio of 0.35. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Senti Biosciences (NASDAQ:SNTI) Stock

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer cells, while sparing healthy cells in the body. The company was incorporated in 2016 and is headquartered in South San Francisco, California.

Receive SNTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Senti Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SNTI Stock News Headlines

May 25, 2023 | americanbankingnews.com

Critical Survey: Senti Biosciences (SNTI) and The Competition

May 24, 2023 | americanbankingnews.com

Senti Biosciences (SNTI) & Its Rivals Financial Review

June 1, 2023 | Vantage Point (Ad)

Instantly Find Hidden Trade Opportunities

There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market.

May 11, 2023 | msn.com

Chardan Capital Maintains Senti Biosciences (SNTI) Buy Recommendation

May 9, 2023 | finance.yahoo.com

Senti Bio Announces First Quarter 2023 Results and Pipeline Updates

May 2, 2023 | finance.yahoo.com

Senti Bio Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2023 Annual Meeting

April 17, 2023 | finance.yahoo.com

Senti Bio Highlights Preclinical Data from Multiple Gene Circuit Enabled Cell Therapy Programs at Annual AACR Meeting

April 14, 2023 | finance.yahoo.com

Senti Bio to Participate in Upcoming Investor Conferences

June 1, 2023 | Vantage Point (Ad)

Instantly Find Hidden Trade Opportunities

March 25, 2023 | americanbankingnews.com

Senti Biosciences (NASDAQ:SNTI) PT Lowered to $2.00

March 24, 2023 | markets.businessinsider.com

Expert Ratings for Senti Biosciences

March 24, 2023 | markets.businessinsider.com

Morgan Stanley Reaffirms Their Hold Rating on Senti Biosciences (SNTI)

March 24, 2023 | americanbankingnews.com

Senti Biosciences (NASDAQ:SNTI) Price Target Lowered to $7.00 at Chardan Capital

March 24, 2023 | benzinga.com

Senti Biosciences Stock (NASDAQ:SNTI), Dividends

March 23, 2023 | finanznachrichten.de

Senti Biosciences, Inc.: Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent Highlights

March 22, 2023 | finance.yahoo.com

Senti Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Reviews Recent Highlights

March 14, 2023 | finance.yahoo.com

Senti Bio Announces Three Preclinical Data Presentations from Gene Circuit-Enhanced CAR-NK Cell Oncology Pipeline at Annual AACR Meeting

February 6, 2023 | finance.yahoo.com

Investors in Senti Biosciences (NASDAQ:SNTI) have unfortunately lost 82% over the last year

February 1, 2023 | finance.yahoo.com

Senti Bio to Present at the SVB Securities Global Biopharma Conference

January 30, 2023 | msn.com

Chardan Capital Maintains Buy Rating for Senti Biosciences: Here's What You Need To Know

January 27, 2023 | marketwatch.com

Senti Biosciences Launches New Strategic Plan, Sees Cash Runway to 1Q 2024

January 27, 2023 | finance.yahoo.com

Senti Bio Announces Pipeline Prioritization to Focus on Logic Gated Cell Therapies; Updates Cash Runway Guidance

December 27, 2022 | finance.yahoo.com

We Think Senti Biosciences (NASDAQ:SNTI) Needs To Drive Business Growth Carefully

December 19, 2022 | finance.yahoo.com

Senti Bio to Present at 41st Annual J.P. Morgan Healthcare Conference

December 11, 2022 | finance.yahoo.com

Senti Bio Highlights Preclinical Data from Logic-Gated Gene Circuit CAR-NK Cell Therapy SENTI-202 at ASH Annual Meeting and Investor Event

November 16, 2022 | finance.yahoo.com

Senti Biosciences Third Quarter 2022 Earnings: Beats Expectations

November 10, 2022 | finanznachrichten.de

Senti Biosciences, Inc.: Senti Bio Reports Third Quarter Financial Results and Pipeline Updates

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive SNTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Senti Biosciences and its competitors with MarketBeat's FREE daily newsletter.

SNTI Company Calendar

Last Earnings: 3/22/2023
Today: 5/31/2023
Next Earnings (Estimated): 8/21/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SNTI
CUSIP: N/A
CIK: 1854270
Web: www.sentibio.com
Phone: 650-239-2030
Fax: N/A
Employees: N/A
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $4.50
High Stock Price Forecast: $7.00
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +409.1%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.08)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-58,210,000.00
Net Margins: -1,457.24%
Pretax Margin: -1,457.24%
Return on Equity: -48.76%
Return on Assets: -35.49%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.26
Quick Ratio: 6.26

Sales & Book Value

Annual Sales: $4.29 million
Price / Sales: 9.10
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.54 per share
Price / Book: 0.35

Miscellaneous

Outstanding Shares: 44,170,000
Free Float: N/A
Market Cap: $39.04 million
Optionable: Not Optionable
Beta: 2.48

Key Executives

Dr. Timothy K. Lu M.D. (Age 41)
Ph.D., Co-founder, CEO, Pres & Director
Comp: $694.21k

Dr. Philip Lee Ph.D. (Age 40)
Co-Founder & CTO
Comp: $571.6k

Ms. Susan D. Berland (Age 67)
Sr. Financial Exec. & Independent Director
Comp: $27.84k

Dr. James J. Collins Ph.D. (Age 56)
Scientific Co-Founder, Chairperson of Scientific Advisory Board & Independent Director

Dr. Wilson Wong Ph.D.
Scientific Co-Founder & Member of Scientific Advisory Board

Dr. Deborah A. Knobelman Ph.D. (Age 48)
CFO & Treasurer

Dr. Kanya Rajangam M.D. (Age 49)
Ph.D., Chief Medical & Devel. Officer

Susan Kahlert
Controller

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

SNTI Stock - Frequently Asked Questions

Should I buy or sell Senti Biosciences stock right now?: 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Senti Biosciences in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SNTI shares.
View SNTI analyst ratings or view top-rated stocks.
What is Senti Biosciences' stock price forecast for 2023?: 4 analysts have issued 1 year price targets for Senti Biosciences' shares. Their SNTI share price forecasts range from $2.00 to $7.00. On average, they predict the company's share price to reach $4.50 in the next year. This suggests a possible upside of 409.1% from the stock's current price.
View analysts price targets for SNTI or view top-rated stocks among Wall Street analysts.
How have SNTI shares performed in 2023?: Senti Biosciences' stock was trading at $1.41 on January 1st, 2023. Since then, SNTI shares have decreased by 37.3% and is now trading at $0.8839.
View the best growth stocks for 2023 here.
When is Senti Biosciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our SNTI earnings forecast.
How were Senti Biosciences' earnings last quarter?: Senti Biosciences, Inc. (NASDAQ:SNTI) announced its earnings results on Wednesday, March, 22nd. The company reported ($0.42) EPS for the quarter, beating analysts' consensus estimates of ($0.47) by $0.05. The firm earned $0.06 million during the quarter, compared to analyst estimates of $1.92 million. Senti Biosciences had a negative trailing twelve-month return on equity of 48.76% and a negative net margin of 1,457.24%.
What ETFs hold Senti Biosciences' stock?: ETFs with the largest weight of Senti Biosciences (NASDAQ:SNTI) stock in their portfolio include ARK Genomic Revolution ETF (ARKG),

What is Senti Biosciences' stock symbol?: Senti Biosciences trades on the NASDAQ under the ticker symbol "SNTI."
Who are Senti Biosciences' major shareholders?: Senti Biosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (7.85%), ARK Investment Management LLC (4.31%) and Triatomic Management LP (0.48%).
View institutional ownership trends.
How do I buy shares of Senti Biosciences?: Shares of SNTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Senti Biosciences' stock price today?: One share of SNTI stock can currently be purchased for approximately $0.88.
How much money does Senti Biosciences make?: Senti Biosciences (NASDAQ:SNTI) has a market capitalization of $39.04 million and generates $4.29 million in revenue each year. The company earns $-58,210,000.00 in net income (profit) each year or ($2.08) on an earnings per share basis.
How can I contact Senti Biosciences?: Senti Biosciences' mailing address is 2875 EL CAMINO REAL, REDWOOD CITY CA, 94061. The official website for the company is www.sentibio.com. The company can be reached via phone at 650-239-2030 or via email at irbd@dspc.bio.

This page (NASDAQ:SNTI) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial